1. Case Studies in Unresectable Hepatocellular Carcinoma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. HCC Overview

5. General Approaches to Treatment

6. General Approaches to Treatment (cont)

7. Case 1

8. Case Discussion

9. Case 1 (cont)

10. RESORCE Trial

11. Phase 3 Trials in Second-Line Settings

12. REFLECT Trial

13. Absence of Correlation Between TTP and OS

14. Case 2

15. Case 2 (cont)

16. Nivolumab CheckMate 040 Trial

17. Panel Discussion

18. Conclusions

19. Abbreviations